Market LIVE
Published markets; coverage varies by country
Product profile · United States

JENTADUETO XR

 ·  Patent Litigation & Settlement History ↓

IngredientLINAGLIPTIN; METFORMIN HYDROCHLORIDE
Application typeNDA
Application208026
Product001
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength2.5MG;1GM
Approval date2016-05-27
Marketing statusPrescription
Status event—
ApplicantBOEHRINGER INGELHEIM
Product source

Current GenericRadar decision

Year2027
SelectionDEEP_REVIEW
ReviewFINAL_CHECKING
Anchor typeDS_EQUIVALENT
Anchor date2027-11-04
Patent anchor2027-11-04
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2027. Anchor type: DS_EQUIVALENT. Patent anchor: 2027-11-04. Exclusivity anchor: not recorded. Anchor date: 2027-11-04. Patent tail: yes. Exclusivity tail: no. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
88838052025-11-26DP ————
———
88838052026-05-26— ————
—2026-05-26—
86739272027-05-04U U-1503———
———
91738592027-05-04DP/U U-1503———
———
86739272027-11-04— ————
—2027-11-04—
91738592027-11-04— ————
—2027-11-04—
100223792029-04-02U U-2339———
———
126784422029-04-02DP ————
———
94150162029-04-02DP ————
———
100223792029-10-02— ————
—2029-10-02—
94150162029-10-02— ————
—2029-10-02—
119113882030-04-10U U-3854———
———
91557052030-05-21DP ————
———
91557052030-11-21— ————
—2030-11-21—
95550012033-03-06DP/U U-1968———
———
95550012033-03-06DP/U U-1967———
———
95550012033-09-06— ————
—2033-09-06—
123647002037-06-08U U-4224———
———
123647002037-12-08— ————
—2037-12-08—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
M-295—2026-06-20————Source
PED—2026-12-20————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.